NLRP3 and diabetes mellitus: Furthermore, echocardiography results of NLRP3-miRNA treated diabetes rats revealed that both the LV systolic and diastolic dysfunction were improved, which were attributed to decreased cardiac cell death, reduced cardiac lipid accumulation, and less cardiac fibrosis; thus, NLRP3 silencing attenuated DCM.